Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial

The Lancet

Volumn 376, Issue 9747, 2010, Pages 1164-1174

  Hallek, M ^a   Fischer, K ^a   Fingerle Rowson, G ^a   Fink, A M ^a   Busch, R ^b   Mayer, J ^c   Hensel, M ^d   Hopfinger, G ^e   Hess, G ^f   Von Grunhagen U ^g   Bergmann, M ^h   Catalano, J ⁱ   Zinzani, P L ^j   Caligaris Cappio, F ^k   Seymour, J F ^l   Berrebi, A ^m   Jager U ⁿ   Cazin, B ^o   Trneny, M ^p   Westermann, A ^a   Wendtner, C M ^a   Eichhorst, B F ^a   Staib, P ^q   Buhler A ^r   Winkler, D ^r   Zenz, T ^r   Bottcher S ^s   Ritgen, M ^s   Mendila, M ^t   Kneba, M ^s   Dohner H ^r   Stilgenbauer, S ^r   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e HANUSCH HOSPITAL   (Austria)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g Gemeinschaftspraxis Hämatologie und Onkologie   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ FRANKSTON HOSPITAL   (Australia)

^j UNIVERSITY OF BOLOGNA   (Italy)

^k Obstetrics and Gynaecology Department   (Italy)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m KAPLAN MEDICAL CENTER   (Israel)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^o LILLE UNIVERSITY HOSPITAL   (France)

^p CHARLES UNIVERSITY   (Czech Republic)

^q St Antonius Hospital   (Germany)

^r UNIVERSITY OF ULM   (Germany)

^s UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^t F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CYTOKINE RELEASE SYNDROME; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROENTERITIS; HEPATITIS B; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; SIDE EFFECT; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; INCIDENCE; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MORTALITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOPENIA; MALE; MIDDLE AGED; NEUTROPENIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIDARABINE;

EID: 77957664665     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61381-5     Document Type: Article

References (41)

1. GM Dores, WF Anderson, RE Curtis Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology Br J Haematol 139 2007 809 819
2. LM Morton, SS Wang, SS Devesa, P Hartge, DD Weisenburger, MS Linet Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 Blood 107 2006 265 276
3. JL Binet, F Caligaris-Cappio, D Catovsky Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia Blood 107 2006 859 861
4. JL Binet, A Auquier, G Dighiero A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis Cancer 48 1981 198 204
5. KR Rai, A Sawitsky, EP Cronkite, AD Chanana, RN Levy, BS Pasternack Clinical staging of chronic lymphocytic leukemia Blood 46 1975 219 234
6. H Döhner, S Stilgenbauer, A Benner Genomic aberrations and survival in chronic lymphocytic leukemia N Engl J Med 343 2000 1910 1916 (Pubitemid 32064784)
7. RN Damle, T Wasil, F Fais Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia Blood 94 1999 1840 1847
8. TJ Hamblin, Z Davis, A Gardiner, DG Oscier, FK Stevenson Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia Blood 94 1999 1848 1854
9. T Han, EZ Ezdinli, K Shimaoka, D Desai Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia Cancer 31 1973 502 508
10. WH Knospe, V Loeb Jr, CM Huguley Jr. Biweekly chlorambucil treatment of chronic lymphocytic leukemia Cancer 33 1974 555 562
11. CLL trialists' collaborative group Chemotherapeutic options in chronic lymphocytic leukemia J Natl Cancer Inst 91 1999 861 868
12. MJ Keating, H Kantarjian, J Redman Fludarabine: a new agent with major activity against chronic lymphocytic leukemia Blood 74 1989 19 25
13. MR Grever, KJ Kopecky, CA Coltman Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia Nouv Rev Fr Hematol 30 1988 457 459
14. D Catovsky, S Richards, E Matutes Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial Lancet 370 2007 230 239
15. BF Eichhorst, R Busch, G Hopfinger Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia Blood 107 2006 885 891
16. IW Flinn, DS Neuberg, MR Grever Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997 J Clin Oncol 25 2007 793 798
17. DG Maloney, B Smith, A Rose Rituximab: mechanism of action and resistance Semin Oncol 29 2002 2 9
18. H Schulz, JF Bohlius, S Trelle Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis J Natl Cancer Inst 99 2007 706 714
19. AS Michallet, B Coiffier Recent developments in the treatment of aggressive non-Hodgkin lymphoma Blood Rev 23 2009 11 23
20. NM Almasri, RE Duque, J Iturraspe, E Everett, RC Braylan Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia Am J Hematol 40 1992 259 263
21. J Golay, M Lazzari, V Facchinetti CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 Blood 98 2001 3383 3389
22. D Huhn, C von Schilling, M Wilhelm Rituximab therapy of patients with B-cell chronic lymphocytic leukemia Blood 98 2001 1326 1331
23. S O'Brien, H Kantarijan, D Thomas Rituximab dose-escalation trial in chronic lymphocytic leukaemia J Clin Oncol 19 2001 2165 2170
24. MJ Keating, S O'Brien, M Albitar Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia J Clin Oncol 23 2005 4079 4088
25. H Schulz, SH Klein, U Rehwald Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia Blood 100 2002 3115 3120
26. JC Byrd, K Rai, BL Peterson Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 Blood 105 2005 49 53
27. W Wierda, S O'Brien, S Wen Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia J Clin Oncol 23 2005 4070 4078 (Pubitemid 46211312)
28. CS Tam, S O'Brien, W Wierda Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Blood 112 2008 975 980
29. BD Cheson, JM Bennett, M Grever National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment Blood 87 1996 4990 4997
30. M Extermann, J Overcash, GH Lyman, J Parr, L Balducci Comorbidity and functional status are independent in older patients J Clin Oncol 16 1998 1582 1587
31. 2-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma Leuk Lymphoma 22 1996 439 447
32. V Kunzmann, T Ruediger, M Hallek, HK Mueller-Hermelink, M Wilhelm Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment Blood 98 2001 1991 1992
33. U Winkler, M Jensen, O Manzke, H Schulz, V Diehl, A Engert Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8) Blood 94 1999 2217 2224
34. H Döhner, K Fischer, M Bentz p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias Blood 85 1995 1580 1589
35. MR Grever, DM Lucas, GW Dewald Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997 J Clin Oncol 25 2007 799 804
36. H Döhner, S Stilgenbauer, MR James 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis Blood 89 1997 2516 2522
37. AM Tsimberidou, C Tam, LV Abruzzo Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia Cancer 115 2009 373 380
38. EJ Schlette, J Admirand, W Wierda p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy Leuk Lymphoma 50 2009 1597 1605
39. C Moreno, N Villamor, D Colomer Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia J Clin Oncol 23 2005 3433 3438
40. J Schetelig, A van Biezen, R Brand Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis J Clin Oncol 26 2008 5094 5100
41. M Hallek, BD Cheson, D Catovsky Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Blood 111 2008 5446 5456